Fondazione Telethon submits EU marketing authorization application for Etuvetidigene Autotemcel Gene Therapy for the treatment of Wiskott-Aldrich Syndrome
30 May 2025
No Comments
Fondazione Telethon announced that it has submitted the Marketing Authorization Application (MAA) for the gene therapy